Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1978 Target Snapshot

Aromatase · SINGLE PROTEIN · Homo sapiens

3,993Compounds
717Assays
21Approved Drugs
5,064.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Aromatase shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P11511. Start with breast cancer, then reuse UniProt P11511 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with breast cancer, then reuse UniProt P11511 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 4 linked drugs
Open source guide
Disease program
breast cancer

Aromatase shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include AMINOGLUTETHIMIDE, ANASTROZOLE, EXEMESTANE, LETROZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Aromatase as ChEMBL target CHEMBL1978, mapped to UniProt P11511. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Aromatase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1978
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P11511
Aromatase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Aromatase is the right protein anchor across sources, using UniProt P11511 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why breast cancer is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelAromatase
UniProt AccessionP11511
Component TypeProtein
Sequence Length503 aa

Aromatase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Aromatase, mapped to UniProt P11511. Sequence length is 503 aa.

Mapped IDP11511
Review nameAromatase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Aromatase shows approved-linked disease relevance led by breast cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
breast cancer
4 linked drugs · 4 direct · 4 efficacy
Linked drugAMINOGLUTETHIMIDE
Linked drugANASTROZOLE
Linked drugEXEMESTANE
Linked drugLETROZOLE
Approved-linked Approved
neoplasm
4 linked drugs · 4 direct · 4 efficacy
Linked drugAMINOGLUTETHIMIDE
Linked drugANASTROZOLE
Linked drugEXEMESTANE
Linked drugLETROZOLE
Approved-linked Approved
breast carcinoma
3 linked drugs · 3 direct · 3 efficacy
Linked drugANASTROZOLE
Linked drugEXEMESTANE
Linked drugLETROZOLE
Approved-linked Approved
breast neoplasm
3 linked drugs · 3 direct · 3 efficacy
Linked drugANASTROZOLE
Linked drugEXEMESTANE
Linked drugLETROZOLE
Approved-linked Approved
cancer
3 linked drugs · 3 direct · 3 efficacy
Linked drugANASTROZOLE
Linked drugEXEMESTANE
Linked drugLETROZOLE
Late clinical Phase III
breast ductal carcinoma in situ
3 linked drugs · 3 direct · 3 efficacy
Linked drugANASTROZOLE
Linked drugEXEMESTANE
Linked drugLETROZOLE
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with breast cancer because it currently carries approved-linked support. Linked drugs include AMINOGLUTETHIMIDE, ANASTROZOLE, EXEMESTANE, LETROZOLE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebreast cancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

21
Approved
6
Phase III
24
Phase II
Assay Mix

Activity Type Distribution

IC504,409.0
KI641.0
EC5014.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4632445 11.0 IC50 0.01 Preclinical
CHEMBL4639677 11.0 IC50 0.01 Preclinical
CHEMBL1672978 10.82 IC50 0.015 Preclinical
CHEMBL1672980 10.82 IC50 0.015 Preclinical
CHEMBL1672979 10.74 IC50 0.018 Preclinical
CHEMBL5438093 10.7 IC50 0.02 Preclinical
CHEMBL1444 10.7 Ki 0.02 Approved
CHEMBL5425028 10.55 IC50 0.02799 Preclinical
CHEMBL468419 10.52 IC50 0.03 Preclinical
CHEMBL310735 10.43 IC50 0.037 Preclinical
Distribution

pChEMBL Value Distribution

678
5.0
624
5.5
647
6.0
565
6.5
575
7.0
322
7.5
213
8.0
137
8.5
92
9.0
48
9.5
pChEMBL
Approved Drugs

Approved Drugs

OSILODROSTAT
CHEMBL3099695
Approved 2020
EXEMESTANE
CHEMBL1200374
Approved 1999
LETROZOLE
CHEMBL1444
Approved 1997
ANASTROZOLE
CHEMBL1399
Approved 1995
KETOCONAZOLE
CHEMBL157101
Approved 1981
AMINOGLUTETHIMIDE
CHEMBL488
Approved 1980
CLOTRIMAZOLE
CHEMBL104
Approved 1975
MICONAZOLE
CHEMBL91
Approved 1974
TESTOSTERONE
CHEMBL386630
Approved 1972
FLUOROURACIL
CHEMBL185
Approved 1962
Assay Landscape

Assay Landscape

717
Total Assays
3,722
Tested Compounds
3
Assay Types
Binding — 687 assays, 3,722 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 301 1,809 6.3
assay format 256 981 6.5
microsome format 68 630 6.1
cell-based format 59 296 7.2
tissue-based format 3 6 7.2
ADME — 17 assays, 52 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 9 17 5.8
cell-based format 4 33 7.3
assay format 3 2 4.9
microsome format 1 0
Functional — 13 assays, 7 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 10 7 6.5
microsome format 3 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine